Literature DB >> 17462779

Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells.

Yasuhiko Yamamoto1, Hideto Yonekura, Takuo Watanabe, Shigeru Sakurai, Hui Li, Ai Harashima, Khin Mar Myint, Mari Osawa, Akihiko Takeuchi, Masayoshi Takeuchi, Hiroshi Yamamoto.   

Abstract

The formation and accumulation of advanced glycation endproducts (AGE) have been implicated in the development of diabetic vascular complications. Their biological responses are known to be mediated by the receptor for AGE (RAGE). Recently, AGE have been proposed to be derived not only from the classical Maillard reaction but also from other pathways of sugar autoxidation and metabolism. Here, we report the identification of glyceraldehydes (Gcer)- and glycolaldehyde (Gcol)-derived AGE as RAGE ligands and their presence in vivo. The apparent dissociation constants assessed by surface-plasmon resonance (SPR) analysis with purified human RAGE proteins were 360 nM for Gcer-AGE and 1.35 microM for Gcol-AGE. The radiolabeled-ligand binding assay with RAGE-expressing COS-7 cells revealed similar association kinetics. Competitive SPR assay with antibodies specific to the respective AGE fractions demonstrated abundant existence of both Gcer- and Gcol-AGE in RAGE affinity-purified proteins from human sera. The serum contents of Gcer- and Gcol-AGE in a diabetic patient were about twice as high as those in a healthy control. Functionally, Gcer- and Gcol-AGE upregulated the endothelial cell levels of mRNA for vascular endothelial growth factor (VEGF) and the secretion of its protein product into the culture media and DNA synthesis in a dose-dependent manner. Further, these endothelial responses were augmented by RAGE overexpression. The results suggest that RAGE engagement of Gcer- and Gcol-AGE may elicit angiogenesis through the induction of autocrine VEGF, thereby contributing to the development and progression of diabetic angiopathies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462779     DOI: 10.1016/j.diabres.2007.01.030

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  16 in total

1.  MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells.

Authors:  Yuhki Sakuraoka; Tokihiko Sawada; Toshie Okada; Takayuki Shiraki; Yoshikazu Miura; Katsuya Hiraishi; Tatsushi Ohsawa; Masakazu Adachi; Jun-ichi Takino; Masayoshi Takeuchi; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy.

Authors:  Makiko Katagiri; Jun Shoji; Noriko Inada; Satoshi Kato; Shigehiko Kitano; Yasuko Uchigata
Journal:  Int Ophthalmol       Date:  2017-03-15       Impact factor: 2.031

3.  Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy.

Authors:  Makiko Katagiri; Jun Shoji; Satoshi Kato; Shigehiko Kitano; Yasuko Uchigata
Journal:  Int Ophthalmol       Date:  2016-11-09       Impact factor: 2.031

Review 4.  Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Tadashi Ueda; Mikihiro Tsutsumi; Hideyuki Hyogo; Sho-Ichi Yamagishi
Journal:  World J Hepatol       Date:  2014-12-27

5.  Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products.

Authors:  Jun-Ichi Takino; Sho-Ichi Yamagishi; Masayoshi Takeuchi
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

6.  Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Sho-Ichi Yamagishi
Journal:  J Ophthalmol       Date:  2010-06-22       Impact factor: 1.909

7.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

8.  Neuropathy induced by exogenously administered advanced glycation end-products in rats.

Authors:  Yusuke Nishizawa; Ryu-Ichi Wada; Masayuki Baba; Masayoshi Takeuchi; Chieko Hanyu-Itabashi; Soroku Yagihashi
Journal:  J Diabetes Investig       Date:  2010-04-22       Impact factor: 4.232

9.  The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk.

Authors:  So Yeon Kong; Masayoshi Takeuchi; Hideyuki Hyogo; Gail McKeown-Eyssen; Sho-Ichi Yamagishi; Kazuaki Chayama; Peter J O'Brien; Pietro Ferrari; Kim Overvad; Anja Olsen; Anne Tjønneland; Marie-Christine Boutron-Ruault; Nadia Bastide; Franck Carbonnel; Tilman Kühn; Rudolf Kaaks; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Pagona Lagiou; Effie Vasilopoulou; Giovanna Masala; Valeria Pala; Maria Santucci De Magistris; Rosario Tumino; Alessio Naccarati; H B Bueno-de-Mesquita; Petra H Peeters; Elisabete Weiderpass; J Ramón Quirós; Paula Jakszyn; María-José Sánchez; Miren Dorronsoro; Diana Gavrila; Eva Ardanaz; Martin Rutegård; Hanna Nyström; Nicholas J Wareham; Kay-Tee Khaw; Kathryn E Bradbury; Isabelle Romieu; Heinz Freisling; Faidra Stavropoulou; Marc J Gunter; Amanda J Cross; Elio Riboli; Mazda Jenab; W Robert Bruce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-09-24       Impact factor: 4.254

10.  Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography.

Authors:  Nobuhiro Tahara; Sho-ichi Yamagishi; Masayoshi Takeuchi; Akihiro Honda; Atsuko Tahara; Yoshikazu Nitta; Norihiro Kodama; Minori Mizoguchi; Hayato Kaida; Masatoshi Ishibashi; Naofumi Hayabuchi; Takanori Matsui; Tsutomu Imaizumi
Journal:  Diabetes Care       Date:  2012-08-21       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.